Results 231 to 240 of about 1,136,503 (270)

Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances

Frontline Gastroenterology
Inflammatory bowel disease (IBD) commonly requires advanced therapies to induce and maintain durable remission. Interleukin (IL)-23 is a proinflammatory heterodimeric cytokine composed of a p40 subunit, which is shared with IL-12 and a unique p19 subunit.
Michael Colwill, Jennifer Clough, Samantha Baillie, Kamal Patel, Laurent Peyrin-Biroulet, Sailish Honap   +5 more
openaire   +1 more source

045 Anti-IL-23 preferentially inhibits pathogenic TH17 cells

Journal of Investigative Dermatology, 2023
Seiringer, P., Eyerich, S., Ranzinger, D., Eyerich, K., Thomas, J., Pilz, A.C.   +5 more
openaire   +2 more sources

Monoclonal antibody anti -IL-23 ameliorates neuromuscular defects in Myasthenia Gravis mouse model

2021
Autoimmune myasthenia gravis (MG) is a rare neuromuscular disease due to auto-antibodies directed against acetylcholine receptors (AChRs) located at the neuromuscular junction. The induced neuromuscular junction (NMJ) dysfunctions lead to muscle weakness and fatigue.
Villegas, Jose Adolfo, Berrih-Aknin, Sonia, Le Panse, Rozen, Dragin, Nadine   +3 more
openaire   +1 more source

Safety of anti‐IL‐23 risankizumab treatment in a patient with severe psoriasis and Charcot–Marie–Tooth disease

Australasian Journal of Dermatology, 2023
Andrea Carugno, Noemi Brigenti, Paolo Gisondi, Zeina Al Ghadban, Michele Parietti, Pamela Vezzoli, Paolo Sena, Chiara Pisciotta   +7 more
openaire   +3 more sources

Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions.

Bone, 2018
P. Shukla, M. N. Mansoori, Divya Singh
semanticscholar   +1 more source

Mpox vaccination in a patient on anti-IL-23 therapy was well tolerated and led to seroconversion

Sexually Transmitted Infections, 2023
openaire   +2 more sources

Anti‐IL‐23 receptor monoclonal antibody prevents CD4+ T cell‐mediated colitis in association with decreased systemic Th1 and Th17 responses

European Journal of Pharmacology, 2018
E. Imamura, K. Taguchi, H. Sasaki-Iwaoka, S. Kubo, S. Furukawa, T. Morokata   +5 more
semanticscholar   +1 more source

Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series

The Journal of Allergy and Clinical Immunology: In Practice, 2023
Hanna Bonnekoh, Lea Kiefer, Thomas Buttgereit, Pavel Kolkhir, Marie Lütke-Eversloh, Jörg Scheffel, Marcus Maurer, Martin Metz   +7 more
openaire   +2 more sources

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

European Journal of Clinical Pharmacology, 2016
Y. Zhuang, C. Calderon, S. Marciniak, E. Bouman‐Thio, P. Szapary, Tong-yuan Yang, A. Schantz, H. Davis, Honghui Zhou, Zhenhua Xu   +9 more
semanticscholar   +1 more source

ISID0045 - Anti-IL-23 preferentially inhibits pathogenic TH17 cells

2023
openaire   +1 more source